Press Releases

BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13

NEW YORK and PETACH TIKVAH, Israel, Aug. 6, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015 financial results on Thursday, August 13, 2015.  The Company will issue a press release before the market opens and will host a conference call at 8:00am Eastern Time to discuss the financial results and answer questions.

 BrainStorm Cell Therapeutics

Conference Call & Webcast

Thursday, August 13, 2015 at 8:00 a.m. EST/5:00 a.m. PST

Domestic:                   888-329-8893
Israel:                         1 80 924 5906
International:                719-325-2354
Conference ID:             5122591

Replay will be available through August 27, 2015

Domestic:                   877-870-5176
International:               858-384-5517
Conference ID:            5122591

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media - Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460,; or Investors - Michael Wood, LifeSci Advisors, LLC, 646-597-6983,
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds